C93.02
BillableAcute monoblastic/monocytic leukemia, in relapse
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C93.02 an HCC code?
Yes. C93.02 maps to Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic under the CMS-HCC V28 risk adjustment model (and Metastatic Cancer and Acute Leukemia under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C93.02
For C93.02to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C93.02 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C93.02 is the ICD-10-CM diagnosis code for acute monoblastic/monocytic leukemia, in relapse. An acute blood cancer affecting monocyte-forming cells that has returned after a period of remission. C93.02 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).
Under the CMS-HCC V28 risk adjustment model, C93.02 maps to Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic (HCC 17) with a community, non-dual, aged base RAF weight of 4.209. Under the older CMS-HCC V24 model, C93.02 maps to Metastatic Cancer and Acute Leukemia (HCC 8) with a community, non-dual, aged base RAF weight of 2.659. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
The '2' suffix indicates relapse; verify documentation shows prior remission before the current recurrence. Because C93.02 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C93.02 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •The '2' suffix indicates relapse; verify documentation shows prior remission before the current recurrence
- •Document the time interval between remission and relapse, as this affects prognosis and treatment planning
Clinical Significance
Acute monoblastic/monocytic leukemia in relapse represents one of the most clinically challenging scenarios, as recurrent monocytic leukemia often shows increased resistance to chemotherapy. Relapsed disease frequently requires more aggressive salvage regimens, including consideration for allogeneic stem cell transplantation.
Documentation Requirements
- ✓Documentation must establish prior remission before coding relapse, including dates and clinical evidence.
- ✓Current relapse documentation should include blast percentage on bone marrow biopsy, peripheral blood findings, any extramedullary disease involvement, and the salvage treatment plan being considered or initiated.